Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Checkpoint Therapeutics Inc (CKPT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Checkpoint Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.420 -0.020    -1.39%
25/04 - Closed. Currency in USD ( Disclaimer )
After Hours
1.420
0.000
0.000%
19:29:34 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 166,048
  • Bid/Ask: 1.410 / 1.520
  • Day's Range: 1.410 - 1.500
Checkpoint Therapeutics 1.420 -0.020 -1.39%

Checkpoint Therapeutics Inc Company Profile

 
Get an in-depth profile of Checkpoint Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

23

Equity Type

ORD

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company’s lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Contact Information

Address 95 Sawyer Road Suite 110
Waltham, 02453
United States
Phone 781 652 4500
Fax 646 619 4950

Top Executives

Name Age Since Title
James F. Oliviero 46 2015 President, CEO & Director
Barry M. Salzman 60 2016 Independent Director
Michael S. Weiss 56 2015 Chairman of the Board
Neil Herskowitz 65 2015 Independent Director
Wayne A. Marasco 68 2015 Chairman of Scientific Advisory Board
Lindsay Allan Rosenwald 67 2014 Non-Executive Director
Emily Ruiz - 2021 Member of Scientific Advisory Board
David Miller - 2021 Member of Scientific Advisory Board
Christian M. Béchon 65 2018 Independent Director
F. Stephen Hodi - 2021 Member of Scientific Advisory Board
Bruce E. Johnson - 2021 Member of Scientific Advisory Board
Roy Steven Herbst 61 - Member of Scientific Advisory Board
Amit Sharma - 2024 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CKPT Comments

Write your thoughts about Checkpoint Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Merter Ortac
Merter Ortac Dec 21, 2023 2:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fda approval will double soon after revisions apllied based on CMO findings.
paola bastoni
paola bastoni Feb 25, 2022 3:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Target price raised to $ 23, prepare for a stratospheric rise at any moment
Hold This Sheet
Hold This Sheet Feb 25, 2022 3:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
When?
paola bastoni
paola bastoni Feb 17, 2022 1:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Target price $ 22,50
MIKHAIL KUZNETSOV
MIKHAIL KUZNETSOV Feb 02, 2022 8:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Long at 2.40s for possible squeeze later. 🚀🚀👍👍
Mahmoud Zaki
Mahmoud Zaki Feb 22, 2021 1:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No call options for this stock?
Igor Ruban
Igor Ruban Feb 12, 2021 10:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I will go up. I have heavy position. 10 shares
Igor Ruban
Igor Ruban Feb 12, 2021 10:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
joninge kvamme
joninge kvamme Feb 12, 2021 10:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What?
Jeff Bailey
JeffB Feb 11, 2021 8:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CKPT $4.16 +12.13% @ Close!
Jeff Bailey
JeffB Feb 09, 2021 1:18PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CKPT $3.99 @ 01:14 PM ET .... selling longs from $2.77 then $2.88.
Jeff Bailey
JeffB Jan 12, 2021 10:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CKPT $3.18 +17.34% @ Close! Bringing stop up to b/e at $2.77
Duane Goodson
Duane Goodson Jan 04, 2021 11:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email